Louisville, KY, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Appriss Health, provider of the most comprehensive platform for substance use disorder in the U.S., today announced it has signed an agreement with Yale New Haven Health to enable the integration of prescription drug monitoring program (PDMP) information directly into electronic health records (EHRs) via Appriss Health’s NarxCare solution. NarxCare is an in-workflow, PDMP information, advanced analytics, tools and technology solution that aids clinical decision-making and increases access to treatment, improves patient engagement, and enables care coordination.
Prior to NarxCare, Yale New Haven Health clinicians needed to log into a separate website to access the Connecticut Prescription Monitoring and Reporting System (CPMRS) to retrieve a patient's controlled substance dispensations from the state database and then cross-reference that data with a patient's health information in their Epic EHR system in what was a cumbersome and time-consuming process. Now, with NarxCare, clinicians are presented with interactive, visual representations of controlled substance presecribing information, advanced analytic insights, risk scores, red flags and more directly in their Epic EHR. NarxCare also extends beyond information and analytics to provide tools and resources to enable care teams to support patient needs.
“Our physicians throughout Yale New Haven Health will now have the critical information they need to make the best prescribing and medical decisions to improve the safety of our patients,” said Allen Hsiao, M.D., chief medical information officer, and associate professor of Pediatrics and of Emergency Medicine at Yale School of Medicine.
“This partnership and integration is one strategy in our Connecticut Opioid Response (CORE) initiative to reduce deaths from opioid overdoses in the state and improve the use of the CPMRS thereby enhancing safe prescribing,” said Gail D’Onofrio, M.D., chief of Emergency Services at Yale New Haven Health, chair of Yale Medicine Operations Committee, and professor and chair of Emergency Medicine at Yale School of Medicine.
“Today, Yale New Haven Health has taken a major step towards improving prescribing decisions and ensuring the best possible patient outcomes,” said Rob Cohen, President, Appriss Health. “We are proud to partner with Yale New Haven Health and the State of Connecticut, not only for the deployment of NarxCare, but to further evaluate the effectiveness of risk scoring and in-workflow integration through studies related to clinical outcomes.”
About Appriss Health
Appriss Health provides the nation's most comprehensive platform for early identification, prevention and management of substance use disorder (SUD). We provide state government agencies with the most advanced repository of controlled substance dispensing data, and deliver real-time clinical decisioning support, critical insights and interventions to physicians, pharmacists, and care team members through millions of patient encounters each year. Our solutions enable healthcare providers, pharmacists, and care team members to assess and manage clinical risk in order to positively impact patient safety and population health outcomes. For more information, please visit www.apprisshealth.com.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/835f7a6f-9798-4421-89f3-50fa37d02ef7